Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Operating activities:
Net income	$ 30,428	$ 106,801
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	13,873	11,137
Acquired in-process research & development	115,490
Bad debt recoveries	(27)	(373)
Stock-based compensation	28,357	20,863
Write-down of inventory and other	6,195	3,122
Accretion on marketable securities	1,768	473
Change in fair value of other investments	(22,440)	(33,872)
Gain on previously held interest in preCARDIA	(20,980)
Deferred tax provision	8,193	14,187
Change in fair value of contingent consideration	108	2,117
Other non-cash operating activities	1,553	2,008
Changes in assets and liabilities:
Accounts receivable	7,444	4,767
Inventories	(11,673)	6,071
Prepaid expenses and other assets	(20,300)	1,744
Accounts payable	(6,266)	(10,128)
Accrued expenses and other liabilities	(15,590)	(21,988)
Deferred revenue	(202)	2,039
Net cash provided by operating activities	115,931	108,968
Investing activities:
Purchases of marketable securities	(333,832)	(294,558)
Proceeds from the sale and maturity of marketable securities and other	326,518	220,197
Purchases of other investments and intangible assets	(3,866)	(3,100)
Proceeds from sales of Shockwave Medical securities		67,882
Purchases of property and equipment	(14,394)	(19,552)
Net cash used for investing activities	(108,395)	(81,314)
Financing activities:
Proceeds from the exercise of stock options	8,382	5,555
Taxes paid related to net share settlement upon vesting of stock awards	(12,129)	(10,934)
Repurchase of common stock		(11,310)
Proceeds from the issuance of stock under employee stock purchase plan	2,961	1,978
Net cash used for financing activities	(786)	(14,711)
Effect of exchange rate changes on cash and cash equivalents	2,422	(3,043)
Net increase in cash and cash equivalents	9,172	9,900
Cash and cash equivalents at beginning of period	232,710	192,341
Cash and cash equivalents at end of period	241,882	202,241
Supplemental disclosure of cash flow information:
Cash paid for income taxes	35,642	25,254
Supplemental disclosure of non-cash activities:
Contingent consideration related to the acquisition of Breethe		13,300
Property and equipment in accounts payable and accrued expenses	578	1,244
Right-of-use assets obtained in exchange for lease liabilities	569	193
Precardia
Investing activities:
Payments for acquisition	$ (82,821)
Breethe
Investing activities:
Payments for acquisition		$ (52,183)